On November 10, according to Novo Nordisk China, Novo Nordisk announced that compensation for the drug patent term of its Novartite® patent related to chronic kidney disease indications has been approved by the State Intellectual Property Office, and the patent protection period for related indications has been extended by 5 years to March 2031.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.